Acute respiratory viral infections in COVID-19 pandemic in practice of polyclinic doctor

2021 ◽  
Vol 1 (11) ◽  
pp. 29-33
Author(s):  
V. V. Nikiforov ◽  
N. V. Orlova ◽  
V. V. Lomaychikov
Keyword(s):  
Differential Diagnosis ◽  
Viral Infections ◽  
Clinical Course ◽  
Respiratory Infections ◽  
Clinical Manifestations ◽  
Acute Respiratory Infections ◽  
Interferon Inducer ◽  
Coronary Syndrome ◽  
Respiratory Viral Infections ◽  
High Level

Acute respiratory viral infections (ARVI), including influenza, remain the most common infectious diseases. In the context of COVID‑19 pandemic, there is a need for differential diagnosis of respiratory syndrome. The clinic of ARVI, depending on the pathogen, may have its own characteristics. Influenza and COVID‑19 have common pathways of transmission of the pathogen and similar symptoms, so the optimal differential diagnosis is the use of test systems for both viruses. Against the background of influenza and other acute respiratory infections, complications from various organs and systems can develop. The article discusses in detail the issues of the clinical course of ARVI, differential diagnosis, modern approaches to therapyand prophylactic. Complications of influenza from the cardiovascular system are considered in detail. The data of our own observations on the risk of developing acute coronary syndrome in persons who have undergone COVID‑19 are presented. Prevention of the development of complications of influenza and other acute respiratory infections is the early appointment of antiviral therapy. Numerous studies confirm the effectiveness of interferon inducers in the treatment of influenza and other ARVI. The article presents the results of clinical studies confirming the effectiveness of therapy with the interferon inducer Kagocel. Against the background of its use, a decrease in the severity of clinical manifestations, a reduction in the duration of the disease, and the prevention of complications were noted. In studies, the drug has shown a high level of safety. The article discusses studies on the effectiveness of chemoprophylaxis of influenza and other acute respiratory infections.

Effectiveness of protected aminopenicillins in treatment of non-social pneumonia in children

2021 ◽  
Author(s):  
Е.Е. Краснова ◽  
В.В. Чемоданов ◽  
Е.Г. Кузнецова
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Acquired Resistance ◽  
Age Groups ◽  
Clinical Manifestations ◽  
Severe Pneumonia ◽  
Physical Symptoms ◽  
Community Acquired Pneumonia ◽  
Natural Activity ◽  
Respiratory Viral Infections

Пневмония – острое инфекционно-воспалительное заболевание легких преимущественно бактериальной этиологии, характеризующееся выраженной в разной степени дыхательной недостаточностью, токсическими и респираторными нарушениями, локальными физикальными симптомами, а также инфильтративными изменениями на рентгенограмме. Заболеваемость внебольничными пневмониями повышается в октябре-декабре, достигая максимума в январе-апреле, коррелируя с сезонным повышением уровня острых респираторных вирусных инфекций. Схожесть симптомов дебюта пневмонии с проявлениями острых респираторных вирусных инфекций может привести к несвоевременной ее диагностике и, как следствие, к отсроченному началу лечения. Поэтому в период сезонной заболеваемости респираторными инфекциями должна повышаться настороженность врачей-педиатров в отношении внебольничной пневмонии. Антибактериальная терапия оказывает решающее влияние на прогноз пневмонии, поэтому при достоверном диагнозе или у больного в тяжелом состоянии с вероятным диагнозом ее следует начать незамедлительно. Выбор антибиотика в каждом случае внебольничной пневмонии проводят индивидуально с учетом природной активности препаратов в отношении предполагаемого возбудителя и их возможной приобретенной резистентности, тяжести и течения заболевания, наличия у пациента противопоказаний к использованию тех или иных антибиотиков. В статье приводятся сведения о диагностических критериях внебольничных пневмоний. Рассмотрены вопросы антибактериального лечения типичной нетяжелой пневмонии у детей разных возрастных групп амоксициллином с клавулановой кислотой и показана его эффективность. Результаты проведенного исследования позволяют заключить, что пероральное использование одного курса защищенного аминопенициллина эффективно при лечении типичной внебольничной нетяжелой пневмонии у детей разного возраста, о чем свидетельствует ликвидация основных клинических проявлений болезни в короткие сроки. Pneumonia is an acute infectious and inflammatory lung disease of predominantly bacterial etiology, characterized by respiratory failure, toxic and respiratory disorders, local physical symptoms, and infiltrative changes on the roentgenogram. The incidence of community-acquired pneumonia increases in October-December, reaching a maximum in January-April, correlating with the seasonal increase in the level of acute respiratory viral infections. The similarity of the symptoms of the onset of pneumonia with the manifestations of acute respiratory viral infections can lead to its untimely diagnosis and, as a consequence, to a delayed start of treatment. Therefore, during the period of seasonal morbidity with respiratory infections, the alertness of pediatricians in relation to community-acquired pneumonia should increase. Antibiotic therapy has a decisive influence on the prognosis of pneumonia, therefore, with a reliable diagnosis or in a patient in serious condition with a probable diagnosis, it should be started immediately. The choice of antibiotic in each case of community-acquired pneumonia is carried out individually, taking into account the natural activity of the drugs in relation to the alleged pathogen and their possible acquired resistance, the severity and course of the disease, the patient's contraindications to the use of certain antibiotics. The article provides information on the diagnostic criteria for community-acquired pneumonia. The issues of antibacterial treatment of typical non-severe pneumonia in children of different age groups with amoxicillin with clavulanic acid are considered and its effectiveness is shown. The results of the study allow us to conclude that the oral use of one course of protected aminopenicillin is effective in the treatment of typical community-acquired non-severe pneumonia in children of different ages, as evidenced by the elimination of the main clinical manifestations of the disease in a short time.

scholarly journals Clinical-epidemiological peculiarities of acute respiratory infections in children from 3 to 12 years and evaluation of effectiveness of antivirus therapy

2019 ◽  
Vol 11 (3) ◽  
pp. 38-45
Author(s):  
S. A. Khmilevskaya ◽  
N. I. Zryachkin ◽  
V. E. Mikhailova
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Molecular Genetic ◽  
Respiratory Viruses ◽  
Acute Respiratory Infections ◽  
Age Group ◽  
Leading Role ◽  
Respiratory Viral Infections ◽  
Acute Respiratory Viral Infection ◽  
Tract Infections

The aim: to study the etiological structure of acute respiratory infections in children aged 3 to 12 hospitalized in the early stages of the disease in the department of respiratory infections of the children’s hospital, and to reveal the features of their clinical course and the timing of DNA / RNA elimination of respiratory viruses from nasal secretions, depending on the method of therapy. Materials and methods: 100 children with acute respiratory infections aged 3 to 12 years were monitored. The nasal secrets on the DNA / RNA of respiratory viruses were studied by PCR. Depending on the method of therapy, patients were divided into 2 groups: patients of group 1 (comparison) received basic treatment (without the use of antiviral drugs), in patients of the 2nd group (main), along with basal therapy, the drug was used umifenovir in a 5-day course at the ageappropriate dosage. Results: In the etiologic structure of ARVI in children from 3 to 12 years, the leading place was taken by rhinovirus, influenza and metapneumovirus infections (isolated – 18%, 19% and 20% respectively, in the form of a mixed infection – 11%). The main syndromic diagnosis at the height of the disease was rhinopharyngitis. Complications were observed in 42% of cases, as often as possible with flu – 53% of cases. Features of metapneumovirus infection in children of this age group were: predominance of non-severe forms of the disease in the form of acute fever with symptoms of rhinopharyngitis, as well as a small incidence of lower respiratory tract infections. The use of the drug umiphenovir in children with acute respiratory viral infections of various etiologies contributed to significantly faster elimination of viral DNA / RNA from the nasal secretion, which was accompanied by a ecrease in the duration of the main clinical and hematological symptoms of the disease, a decrease in the incidence of complications, and reduced the duration of stay in hospital. Conclusion: application of modern molecular genetic methods of diagnostics made it possible to identify the leading role of influenza, metapneumovirus and rhinovirus infections in the etiology of acute respiratory viral infection in patients aged 3 to 12 years, and to determine a number of clinical features characteristic of this age group. The results of the study testify to the effectiveness of umiphenovir in the treatment of children with acute respiratory viral infections of various etiologies and allow us to recommend this drug as an effective and safe etiotropic agent.

scholarly journals Recurrent respiratory viral diseases and chronic sequelae due to dominant negative IFIH1

2020 ◽  
Author(s):  
Christin L Deal ◽  
Timothy J Thauland ◽  
Rebecca Signer ◽  
Stanley F Nelson ◽  
Hane Lee ◽  
...  
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Clinical Manifestations ◽  
Dominant Negative ◽  
Dominant Negative Effect ◽  
Compound Heterozygous ◽  
Loss Of Function ◽  
Negative Effect ◽  
Respiratory Viral Infections ◽  
Compound Heterozygous Variants

Viral respiratory infections are the most common childhood infection worldwide. However, even common pathogens can have significant consequences in the context of patients with primary immunodeficiency diseases. More than half or viral infections annually are due to rhinovirus/enterovirus strains. Most clinical manifestations of viral infection are mild. However 3% of cases result in hospitalization in patients who have no other known risk factors. These patients may have an inborn error of immunity, a genetic susceptibility to viral infections. Here we present the case of an adult male who suffered respiratory viral infections his whole life and developed chronic, inflammatory damage to sinuses and lungs as a consequence. Genomic sequencing identified compound heterozygous variants in the IFIH1 gene, encoding the protein Melanoma Differentiation Association Protein 5 (MDA5), a RIG-I-like cytoplasmic sensor of RNA intracellular infections. We show a dominant negative effect on these variants on the level of interferon-induced expression of MDA5 protein. This work supports that loss-of-function variants in IFIH1 affect the sensing of viral infections. Underlying genomic variants may dictate the point at which recurrent, respiratory viral infections leave commonplace experience and incur lasting damage.

scholarly journals Respiratory viral infections in children: modalities for pathogenic treatment

2021 ◽  
Vol 5 (11) ◽  
pp. 762-767
Author(s):  
S.V. Nikolaeva ◽  
◽  
Yu.N. Khlypovka ◽  
V.A. Zavolozhin ◽  
E.K. Shushakova ◽  
...  
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Rapid Identification ◽  
Influenza Viruses ◽  
Epidemiological Surveillance ◽  
Acute Respiratory Infections ◽  
Emerging Viruses ◽  
Therapeutic Measures ◽  
Respiratory Viral Infections ◽  
Rhinovirus C

Respiratory viruses are the leading cause of pediatric morbidity and mortality worldwide. Rapid identification of a pathogen, epidemiological surveillance, description of symptoms, and the development of preventive and therapeutic measures are keystones to limit the spread of respiratory infections. Novel viruses with specific properties are regularly discovered. This paper addresses essential data on the most common viruses provoking acute respiratory infections, including whose in children and the pattern of their course. Conventionally, the most vital concern is flu. Influenza viruses provoke seasonal outbreaks, epidemics, and pandemics. Many studies demonstrate the role of rhinovirus C in the development of bronchiolitis and, subsequently, asthma. Severe acute respiratory syndrome-related coronavirus (SARS-CoV), Middle East respiratory syndrome-related coronavirus (MERS-CoV), and SARS-CoV-2 provoking COVID-19 were recently described. Knowledge of known and newly emerging viruses is crucial for timely adequate medical care. The authors discuss major therapeutic strategies for acute respiratory infections that provide a more favorable course of infectious inflammation irrespective of viral etiology. KEYWORDS: acute respiratory infections, influenza virus, rhinovirus, coronavirus, pneumonia, interferon. FOR CITATION: Nikolaeva S.V., Khlypovka Yu.N., Zavolozhin V.A. et al. Respiratory viral infections in children: modalities for pathogenic treatment. Russian Medical Inquiry. 2021;5(11):762–767 (in Russ.). DOI: 10.32364/2587-6821-2021-5-11-762-767.

scholarly journals Efficacy and safety of Anaferon for children and Anaferon for the prevention and treatment of influenza and other acute respiratory viral infections: systematic review and meta-analysis

2021 ◽  
Vol 5 (5) ◽  
pp. 335-347
Author(s):  
N.A. Geppe ◽  
◽  
A.L. Zaplatnikov ◽  
E.G. Kondyurina ◽  
O.I. Afanasieva ◽  
...  
Keyword(s):  
Systematic Review ◽  
Therapeutic Efficacy ◽  
Disease Duration ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Meta Analysis ◽  
Acute Respiratory Infections ◽  
Efficacy And Safety ◽  
Prevention And Treatment ◽  
Respiratory Viral Infections

Aim: to evaluate the efficacy and safety of Anaferon and Anaferon for children for the prevention and treatment of of acute respiratory viral infections (ARVI)/influenza using meta-analysis. Patients and Methods: the meta-analysis included data from 11 randomized clinical trials (RCTs) involving 3079 patients aged 1 month to 69 years, of which: 1729 people were included in the meta-analysis of the preventive drugs efficacy, 1550 patients — in the meta-analysis of the therapeutic efficacy of Anaferon for children. The evaluation of the therapeutic efficacy was conducted according to the criteria "disease duration" and/or "fever duration", the evaluation of the preventive efficacy was conducted according to the criterion "the proportion of patients not falling ill with ARVI/influenza". The safety was evaluated taking into account the number of adverse events (AEs). Statistical methods included the exact Fisher criterion, the Student criterion, fixed and random effects models, the Z-test, the Cochrane-Mantel-Hensel criterion, Cochrane Q-statistics and the I2 coefficient, the Breslow-Day test, the calculation of relative risk (RR), odds ratios (OR) and their 95% confidence intervals (CI). Results: according to the criterion "the proportion of patients not falling ill with ARVI/influenza", the RR of Anaferon for children was 1.2 [95% CI 1.2; 1.3] with an OR of 2.2 [95% CI 1.7; 2.9], while for Anaferon, the RR was 6.7 [95% CI 3.8; 11.8] with an OR of 20.1 [95% CI 9.2; 44.0]. At the same time, the proportion of patients without ARVI/influenza during Anaferon intake exceeded that in the absence of preventive intervention by almost 8 times, and during Anaferon for children intake — 1.3 times vs. placebo. When evaluating the therapeutic effect of Anaferon for children, it was found that the average disease duration was 1.4 times shorter than during placebo intake, and was 4.71±2.53 days (p<0,001). The average fever duration was 2.19±1.21 days vs. 3.22±1.81 days during placebo intake (p<0,001). According to the criterion "disease duration", the weighted average effect value was 1.05 [95% CI 0.44; 1.67], according to the criterion "fever duration" — 0.97 [95% CI 0.61; 1.33] (p<0.001, p-value of the two-tailed Z-test; random effects model). The therapeutic efficacy of Anaferon for children did not depend on the etiology of ARVI, the symptoms, and the presence of comorbidity (asthma). The total number of AEs is similar to those in the comparison group. Conclusion: the conducted review and meta-analysis concerning the efficacy and safety of Anaferon and Anaferon for children for the treatment and prevention of ARVI/influenza allow us to conclude the following: 1) Anaferon for children is effective and safe for the treatment of influenza and other acute respiratory infections, regardless of the pathogen and the presence of comorbidity (asthma); 2) Anaferon and Anaferon for children are effective and safe for the prevention of acute respiratory infections/influenza, including patients with concomitant bronchopulmonary pathology and frequently ill children. KEYWORDS: ARVI, influenza, prevention, treatment, meta-analysis, Anaferon, Anaferon for children. FOR CITATION: Geppe N.A., Zaplatnikov A.L., Kondyurina E.G. et al. Efficacy and safety of Anaferon for children and Anaferon for the prevention and treatment of influenza and other acute respiratory viral infections: systematic review and meta-analysis. Russian Medical Inquiry. 2021;5(5):335–347 (in Russ.). DOI: 10.32364/2587-6821-2021-5-5-335-347.

scholarly journals Probiotics for prevention of acute respiratory infections in children: therapeutic potential.

2021 ◽  
pp. 254-260
Author(s):  
Irina N. Zakharova ◽  
Narine G. Sugyan
Keyword(s):  
Respiratory Tract ◽  
Bacterial Infections ◽  
Viral Infections ◽  
Therapeutic Potential ◽  
Respiratory Infections ◽  
Short Chain Fatty Acids ◽  
Acute Respiratory Infections ◽  
Human Respiratory Tract ◽  
Local Immunity ◽  
Respiratory Viral Infections

Acute respiratory viral infections represent a group of clinically, pathomorphologically similar acute inflammatory respiratory diseases that manifest by fever, a runny nose, sneezing, cough, sore throat, a general feeling of ill health of varying severity. Activation of latent, persistent infections of viral and/or bacterial origin may occur in recurrent respiratory infections. Decreased production of local immunity contributes greatly to the development of viral and bacterial infections, persistence of pathogenic micro-organisms. Intestinal microflora can directly or indirectly affect the human respiratory tract through increased production of cytokines, short-chain fatty acids. In recent years, there has been a scientific interest in the therapeutic potential of probiotics for the prevention of acute respiratory viral infections. Earlier studies have shown a positive effect of probiotics on the respiratory tract with a view to prevent and reduce the incidence and severity of respiratory infectious diseases by expending the number of IgA secreting cells in the bronchial mucosa. Studies showed that the use of probiotics can reduce the incidence of acute respiratory infections, duration of fever, cough, and the need for antibacterial agents in children. Peptidoglycans and muramyl peptides that are constituents of the bacterial cell wall have antiviral activity. Probiotics can also inhibit virus attachment through a process of competing for the specific receptors. The regeneration of the mucous membrane is enhanced by the ability of mucin to prevent the virus from attaching to epithelial cells and suppress virus replication. The antiviral effect of probiotics may be caused by the ability to produce antimicrobial peptides, dehydrogenases and NOs. Probiotics can modulate the functions of epithelial and dendritic cells, CD4 +, CD8 + T lymphocytes, NK cells, stimulate the synthesis of secretory immunoglobulins, helping to neutralize the virus.

scholarly journals Clinical efficacy of acute respiratory viral infections prevention in patients with chronic heart failure

2019 ◽  
Vol 91 (3) ◽  
pp. 36-41 ◽  
Author(s):  
A V Budnevsky ◽  
A D Shurupova ◽  
A Ya Kravchenko ◽  
R E Tokmachev
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Standard Therapy ◽  
Hospital Admissions ◽  
Viral Infections ◽  
Clinical Course ◽  
Functional Class ◽  
Dynamic Monitoring ◽  
Interferon Inducer ◽  
Respiratory Viral Infections

The aim of the study was to evaluate the ARVI prevention effectiveness in patients with chronic heart failure (CHF) using interferon inducer amixin. Materials and methods. Conducted a comprehensive survey, dynamic monitoring and treatment of 60 patients aged from 49 to 70 years (mean age 60.25±4.57 years, 17 men and 43 women) with CHF with preserved ejection fraction of left ventricle (LVEF) (≥50%), II-III functional class (FC) according to the classification of new York Heart Association (NYHA), which developed as a result of coronary heart disease (CHD), hypertensive disease (HD). Of these, 30 patients (group 1) on the background of standard therapy for CHF received for the prevention of ARVI tiloron (Amixin) at a dose of 125 mg once a week for 6 weeks, two courses for 1 year. Group 2 patients received only standard therapy for CHF. Results. A decrease in the frequency of ARVI in patients with CHF treated with Amixin was found, which was accompanied by a decrease in the severity of subclinical inflammation by reducing the production of proinflammatory (IL-1β) and increasing the production of anti-inflammatory (IL-10) cytokines, reducing neurohumoral activation (reducing levels of aldosterone and Nt-proBNP), increasing the level of α- and γ-interferon. The positive dynamics of biomarkers of systemic inflammation and neurohormonal activation explains the improvement of the clinical course in patients with CHF (increase of tolerance to physical loads, reducing the number of visits to General practitioner and hospital admissions in the hospital during 12 months of observation). Conclusion. A promising approach to the prevention of SARS in patients with CHF is course therapy with Amixin (2 times a year before the seasonal rising in the incidence of respiratory viral infections and influenza), which allows to achieve both decreasing in the frequency of SARS per year, and improvement the clinical course of CHF.

scholarly journals The bacteriological research in case of acute respiratory infections: actual, informative and effective

2018 ◽  
Vol 22 (2) ◽  
pp. 394-397
Author(s):  
S. I. Klymnyuk ◽  
L .B. Romanyuk ◽  
L .A. Volianska ◽  
E .I. Burbelа ◽  
N. Ya. Kravets ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Family Doctor ◽  
Clinical Manifestations ◽  
Risk Groups ◽  
Symptomatic Therapy ◽  
Acute Respiratory Infections ◽  
Family Doctors ◽  
Opportunistic Bacteria

The most common nosology in the routine work of family doctors is acute respiratory infections. The etiological composition of the acute respiratory viral infections is changing from year to year, which causes difficulties with the use of treatments. Purpose - improvement of tactics of a family doctor for antibiotic therapy of acute respiratory infections. Clinical manifestations of all etiological forms of ARI are similar, which complicates their differentiation. One of the leading - respiratory syndrome, is determined by the local defeat of certain parts of the respiratory tract. The pathogens of these diseases are mainly viruses, but the role of bacteria is also indisputable. According to the results of bacteriological studies with ARI, pathogens often include opportunistic bacteria of the staphylococcus group, streptococci, other aerobic and anaerobic cocci, representatives of the intestinal group and Candida, which can cause antibiotic-resistant forms. The family doctor should establish the diagnosis of respiratory infections, solve the problem of symptomatic therapy and agree on a strategy for the appointment of antibiotics. Most acute respiratory infections even in the absence of antibiotic therapy are recovering. Therefore, the tactics for the appointment of antibiotics should be determined depending on the severity of the disease, the belonging of the patient to certain risk groups. It would be advisable to include the collection of information on previous bacteriological studies and the preliminary history of the use of antibacterial agents, which would allow a family doctor to be better targeted when prescribing antibiotic therapy. The algorithm of the physician's action in the case of acute respiratory infections should be expanded at the point of coordination of the strategy of antibiotic therapy, adding to it the purpose of bacteriological examination in each case of diagnosis of ARI.

The clinical end epidemiological characteristics of influenza and acute respiratory infections in North Ossetia-Alania

2015 ◽  
Vol 21 (31) ◽  
pp. 65-68
Author(s):  
Гуриева ◽  
Z. Gurieva ◽  
Плиева ◽  
Zh. Plieva ◽  
Гипаева ◽  
...  
Keyword(s):  
Immune Response ◽  
Viral Infections ◽  
Preventive Measures ◽  
Respiratory Infections ◽  
Acute Respiratory Infections ◽  
Medical Problems ◽  
The North ◽  
Respiratory Viral Infections ◽  
Epidemiological Characteristics ◽  
North Ossetia

The influenza and acute respiratory infections are one of the medical problems. The relevance of influenza and acute respiratory infections was due to the lack of a persistent immune response and the lack of vaccines against many respiratory viral infections. We have analyzed the latest outbreak of influenza and acute respiratory infections in the North Ossetia-Alania, that occurred in winter 2015. During the analyzed period there was an increase in the incidence of acute respiratory infections by 42,1%. 66 cases of influenza were revealed by the laboratory. In order to reduce the intensity of flu and acute respiratory infections is necessary to observe all types of preventive measures: specific vaccination, chemoprophylaxis with antivirals and following the rules of non-specific prevention.

Sign in / Sign up

Export Citation Format

Share Document